Objectives: Based on qualitative research of patients with chronic obstructive pulmonary disease (COPD), the Shortness of Breath (SOB) with Daily Activities (SOBDA) questionnaire was developed as a patient-reported outcome instrument to evaluate the impact of therapy on SOB and assess how SOB affects daily activities. Methods: Development of the SOBDA questionnaire consisted of three components. First, focus groups of patients with COPD were asked to describe their experiences of SOB with daily activities. A pool of items was drafted on the basis of information from the focus groups and literature reviews, and then discussed among instrument development and clinical experts. Cognitive debriefing interviews of patients were conducted to assess the draft item pool, and their feedback was used to develop newer versions of the questionnaire. Input was also sought from the Food and Drug Administration, patients, and clinicians. Results: Forty patients participated in seven focus groups. The terms most often used to describe SOB were ''short of breath'' or ''difficulty breathing.'' Patients were clearly able to distinguish SOB from chest congestion and wheezing, other common symptoms associated with COPD. The resulting item pool contained 37 items to assess SOB associated with everyday activities, and concept saturation was reached. Thirty-seven patients participated in the subsequent cognitive debriefing interviews. Patients found the items clear and easy to understand with relevance to their everyday experiences, and easy to use in an electronic format. Conclusions: Instructions and response options to the SOBDA questionnaire were well understood by patients with COPD, and item relevance was confirmed. Prospective validation and item reduction studies are highly anticipated.
Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by progressive airflow limitation that is not fully reversible [1] . It is associated with an abnormal inflammatory response in the lung to noxious particles or gases.
The principal marker for the physiologic changes in airflow limitation, which is characteristic of the disease, is lung function, measured as forced expiratory volume in 1 second (FEV1). This marker correlates poorly with the severity of dyspnea (usually described by patients as shortness of breath [SOB] ) and other symptoms of COPD [1, 2] . Therefore, changes in FEV1 may not always reflect symptomatic changes that are clinically meaningful for patients. A variety of biologic, physiologic, and symptomatic markers are currently being explored as alternative methods for assessing disease severity, response to therapy, and disease progression [3] [4] [5] .
Dyspnea is one of the most common and disabling symptoms in COPD [3, 6, 7] . It is frequently associated with decreases in functional status, physical activity, and quality of life [8] [9] [10] . The therapeutic goals for patients with COPD include relief from symptoms such as dyspnea, improving health status, preventing and treating exacerbations, slowing the progression of disease, and reducing mortality [1, 11] . Licensed indications for most current COPD treatments are limited to improving airflow obstruction, and yet no US Food and Drug Administration (FDA)-approved pharmacologic therapy currently has information on dyspnea in its US label. As dyspnea is so important to the lives of patients with COPD and it affects many of their daily activities, the relationship between the two is important to properly evaluate.
The relationship between physical activity and breathlessness in COPD is complex, and various models have been developed to help facilitate an understanding of this association. Jolley and Moxham [9] described a physiologic model of patient-reported breathlessness based on the relationship between ventilatory load, respiratory muscle capacity, neural respiratory drive, and neuromechanical dissociation during daily activities. Conversely, Victorson et al. [12] developed a conceptual model to inform patient-reported outcome (PRO) instrument development using patient descriptions of dyspnea and functional limitations in COPD. On the basis of qualitative research, Victorson's group concluded that five primary components make up the patient's experience of dyspnea: breathlessness, fatigue, activity modification, activity limitation, and emotional response. Their model describes how dyspnea symptoms impair function and are mediated by personal and environmental factors. Both the physiologic and conceptual models provided a structure on which to base Shortness of Breath with Daily Activities (SOBDA) questionnaire development for measuring the severity of breathlessness during daily activities. With the understanding gained from these models, we attempted to assess qualitative outcomes in COPD relating to dyspnea.
Qualitative studies are increasingly recognized to be as important to our understanding of the patient experience of dyspnea as studies focusing on other physical aspects of COPD. The results of such studies explain, at least in part, why two people with the same physiologic markers of COPD severity often experience and describe different levels of dyspnea. To develop an instrument that accurately captures how patients perceive dyspnea, a patient-centered approach using their words to describe symptoms is necessary. Such an instrument needs to be valid, reliable, and responsive to change, meeting the criteria outlined in the FDA PRO Guidance document [13] , if the intent is to support a label claim for a medicinal product in the United States. No instruments for assessing COPD-related dyspnea have been qualified for the target population to achieve an indication of a medicinal product by the FDA for inclusion into product labels at the time of writing. We developed the SOBDA questionnaire to assess the impact of daily activities on dyspnea in patients with COPD. The goal of this phase of development was to construct an instrument for assessing SOB during patient-identified daily activities that is based on patient feedback on specific terminology and patient experiences with SOB.
Methods
The process for developing the SOBDA questionnaire involved multiple steps and review processes. Focus groups of patients with COPD were conducted in clinic offices and meeting rooms in San Diego, CA, San Antonio, TX, New Brunswick, NJ, and Miami, FL, and each session lasted for approximately 1.5 to 2 hours. The moderator's discussion guide for the focus groups was developed on the basis of current relevant literature, learnings from previous models such as those developed by Jolley and Moxham [9] and Victorson et al. [12] , and input from clinical experts, and was used to facilitate discussions on patients' experiences of SOB with daily activities. A pool of items was drafted on the basis of information gathered from the focus groups and literature reviews, and these items were then discussed among instrument development and pulmonary experts. In addition, four translation experts and a lexibility expert reviewed the questionnaire to ensure cross-cultural equivalence and translational feasibility, as well as clarity of wording. Cognitive debriefing interviews of patients were subsequently conducted to evaluate the draft item pool, and feedback from these interviews was used to develop newer versions of the questionnaire.
Patients
For both the focus group discussions (phase 1) and cognitive debriefings (phase 2), efforts were made to recruit from pulmonary clinics in the United States participants with a variety of educational, sociodemographic, and ethnic backgrounds, as well as diverse disease experiences. The demography and clinical characteristics of the recruited participants were intentionally chosen to include and expand beyond that of a typical COPD clinical trial population in order for the instrument to be able to be used in a broader trial population. Economic diversity was addressed by using zip codes as a surrogate for socioeconomic status [14] . Clinics from across the United States were instructed to enroll participants with different disease severities to achieve the following target population: 15% Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I, 35% GOLD stage II, 35% GOLD stage III, and 15% GOLD stage IV. The target number of desired participants for this study was 40; however, the total number could be modified on the basis of whether concept saturation (i.e., no new concepts or information emerging from subsequent focus groups) was reached [15] [16] [17] [18] . Saturation was expected to be reached during focus group discussions by approximately 30 patients. If saturation was not reached, additional participants could be added. Protocols were approved by an institutional review board, and patient consent was obtained prior to the discussion of study-related materials. Clinicians completed an enrollment form, confirming each patient's eligibility and disease severity.
Inclusion criteria were as follows: 40 to 80 years of age; current or former smokers with a history of at least 10 packyears; current diagnosis of COPD and/or chronic bronchitis as defined by the GOLD initiative [1] ; willing and able to provide written informed consent; able to participate in a group discussion; and able to speak and read English.
Exclusion criteria were as follows: respiratory disorders other than COPD (e.g., asthma); organic heart disease with resultant left ventricular failure and New York Heart Association class II to IV; clinically relevant bronchiectasis; recent COPD exacerbation (within previous 60 days); neuromuscular disease; possible causes of significant dyspnea/fatigue other than COPD, including severe anemia; and concurrent medical or psychiatric condition or cognitive impairment potentially affecting participation in the study.
Measures
Upon completion of both the focus group discussions and cognitive debriefings, all patients completed a brief sociodemographic questionnaire that provided reviewers with additional information on the patient population. In addition, patients were assessed by using the following validated measures: the modified Medical Research Council dyspnea scale [19] , the St. George's Respiratory Questionnaire for COPD patients [20, 21] , and the Chronic Respiratory Questionnaire -Self-Administered Standardized [22] [23] [24] .
Focus Groups
Moderators used a standardized discussion guide to solicit terminology used by patients to describe the sensation of dyspnea and to explore the circumstances in which participants experienced the sensation. Patients were initially asked to ''tell me about your breathing,'' which prompted them to explain their experience with dyspnea and the differences in sensations of dyspnea compared with chest congestion, chest tightness, and wheezing. Patients were then asked to describe the general activities they conducted on a daily basis, as well as their level of dyspnea as they conducted these activities. Moderators probed on specific dyspnea-inducing aspects of the activities, and patients were asked to describe any body movements or positions that impact dyspnea. All discussion probes were phrased as open-ended questions, using only the terminology that patients provided. The verbatim terms that patients used to describe their dyspnea were coded for the frequency of occurrence. As each concept reached saturation, final sessions were focused on supplementing missing information relating to activities, but an open discussion of the other topics was still encouraged by the moderators.
VA L U E I N H E A L T H
1 5 ( 2 0 1 2 ) 1 0 4 2 -1 0 5 0
Item Pool Development
Based on the literature review and results of the focus groups, a pool of items was drafted and discussed among instrument development and clinical experts. The draft pool was adjusted to improve grammar and ensure cross-cultural equivalence and translational feasibility according to standard cross-cultural translation and adaption processes [25] . Response options were based on the focus group results and modified to include feedback on all levels of dyspnea.
As the SOBDA questionnaire was intended to be completed daily using an electronic format, the items were loaded onto a LogPad personal digital assistant by PHT Corporation. Items and responses too long to fit on the screen were adjusted; the shortening of items and responses is a standard procedure when transitioning from paper to an electronic format and did not require significant changes to the wording of existing items [26] . A review by translation experts and a lexibility expert resulted in Version 1.0 of the SOBDA questionnaire.
Cognitive Debriefing Interviews
Four rounds of one-to-one cognitive debriefing interviews were conducted in San Antonio, TX, New Brunswick, NJ, and Topeka, KS. An interview guide with structured and open-ended questions was developed to optimize consistency. Probes were also used to understand how patients interpreted wording in the questionnaire and how they selected their response. The response options (slightly, moderately, severely, and so severe that I could not do the activity) were based on the commonly used Likert scale [27] , and patients were asked whether these options were meaningful in terms of their own SOB experience. For each of the response options, patients were asked to provide an activity causing them to experience that level of SOB. Stick figures were used to demonstrate body positions associated with various activities because of the impact certain positions have on SOB. During each interview, patients were shown stick figures in various positions and asked what activities they may conduct in such positions. These figures were included as a referent for the activity described in the text as well as to provide a starting point from which activities could be culturally adapted during the translation process. Although the activities could be altered on the basis of cultural relevance, the body position represented by the stick figures remained the same. The interview guide was updated after each round of interviews, on the basis of patients' comments.
During each round of cognitive interviews, the electronic format of the SOBDA questionnaire was used. Version 1.0 of the SOBDA questionnaire was used in the first two rounds of cognitive debriefing interviews, and this was then refined on the basis of participant feedback and suggestions. Version 1.1 was administered during the third round of interviews, and further changes were subsequently made. The resulting Version 1.2 was reviewed internally by GlaxoSmithKline experts and updated, and Version 1.3 was submitted as part of a briefing package to the FDA. The questionnaire was modified on the basis of FDA feedback, after which Version 1.4 was developed and used during a fourth round of interviews, conducted in Houston, TX, and Topeka, KS. Patients were asked to ''think aloud'' when they read each question, and to describe the time frame and factors they considered when selecting their response. Also, patients were asked whether they understood the instructions and could explain them in their own words.
Data Analysis
Descriptive statistics (mean, SD, and frequency) were used to characterize the focus group and cognitive debriefing samples in terms of sociodemographic, health status, and clinical characteristics.
Focus group data analysis focused on establishing content validity of the information gathered [13] and was based on audiotapes, notes taken by the moderator, and moderator recall of the discussions. The evaluation included 1) generation of key words, phrases, and quotes; 2) rating of these attributes by importance (based on the frequency of which symptoms were mentioned within and between focus groups); and 3) identification of additional themes relevant to participants' experiences. A qualitative analysis software program, ATLAS.ti Version 5.0 [28] , facilitated the process. From the evaluation process, a preliminary coding dictionary was developed by a team composed of four members, including two focus group moderators. Words and phrases were selected and grouped into key themes, attributes, concepts, and relationships. Subsequent revisions were made by the team to refine the concepts and respective definitions.
Focus Group Saturation
The FDA guidance requires evidence of saturation to establish content validity in the development of PRO instruments designed for use as clinical trial end points [13] . The number of participants needed to reach saturation is largely driven by the complexity of the concept and the diversity of the participants.
The qualitative data were examined following the focus groups for specific issues and concerns associated with the SOBDA questionnaire. Instrument revisions were considered on the basis of cognitive debriefing interviews. Qualitative data from the last round of interviews were compared with earlier data to explore patients' interpretation of the items, which enabled the degree of saturation to be assessed.
Results

Focus Group Discussions
Participant demography and clinical characteristics
Phase 1 (concept elicitation) consisted of seven focus group discussions. A total of 40 patients participated in these focus groups that were conducted in California, Texas, New Jersey, and Florida over a 3-month period. Demographic and clinical characteristics of the patients are provided in Table 1 .
Emerging themes and concepts and patient description of dyspnea
No differences were found in the descriptions of dyspnea, or activities/experiences with dyspnea between genders or across ethnic or socioeconomic backgrounds. Throughout all focus groups, patients described a feeling of not being able to breathe deeply enough to pull a sufficient amount of air into their lungs. They felt that their lungs could not expand enough to get a full breath of air and described the struggle they had in overcoming the perceived restriction.
The terms ''shortness of breath,'' ''difficulty breathing,'' ''labored breathing,'' ''can't breathe,'' and ''out of breath'' were frequently used to describe the sensation of dyspnea from COPD. Among all ethnic groups, the expressions ''short of breath'' or ''difficulty breathing'' were used most often.
There was consistent distinction between SOB and chest congestion, chest tightness, and wheezing. Chest congestion was described as the sensation of having phlegm or mucus in the chest or throat, with the need to expel or cough. When the moderator probed further, patients reinforced that chest congestion was very different from SOB. Patients often discussed chest tightness in conjunction with SOB, but patients confirmed that these were two different feelings. Most times, chest tightness was described as being a precursor or an indicator that they would not be able to take the next breath as easily. Wheezing was associated with the sound of having phlegm or mucus stuck in the chest or throat.
Some patients were unaware of when they were wheezing, while others were highly bothered by the noise. All patients emphatically concluded that wheezing was different from being short of breath.
SOB with Activity
Patients provided a variety of activities in which they experienced SOB. Throughout the group sessions, it became increasingly evident that SOB with some activities had a greater association with body position, as well as the level of exertion. Many patients experienced an increased level of SOB simply by sitting down and bending to tie their shoelaces. A number of body positions were identified in which patients experienced SOB; patients were asked to identify activities they might do in those positions. Fig. 1 includes a symptom model from the patient perspective. This disease model demonstrates the link between the SOBDA questionnaire items and the pathophysiologic factors associated with SOB. Table 2 provides patients' descriptions of SOB and SOBrelated limitations. Table 3 presents evidence that saturation of the various components of dyspnea described was met through the seven focus VA L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 4 2 -1 0 5 0 groups in this study. Specifically, saturation was met in the terminology that patients use to describe dyspnea (''short of breath,'' ''can't catch breath,'' and ''trouble breathing''), body positions (e.g., bending or reaching), and activities when patients experience dyspnea (showering, dressing, housework, exercise, etc.). It was therefore determined that additional focus groups were not necessary. Spontaneous versus probed tallies were not made during the focus groups as concepts were spontaneous only for the first time one patient mentions a concept; it is probed thereafter because the concept is already known to patients and they no longer have the opportunity to be spontaneous.
Focus Group Saturation
Item Pool Development
Item wording
Key words used by the patients (e.g., ''short of breath'' and ''dressing'') were instrumental in the development of each item. The importance of key words was determined on the basis of the frequency with which a particular word was used. Body positions of the stick figure illustrations were described by the patients and entered into a grid, followed by activities identified by the patients for each body position. Response options were also chosen on the basis of patient descriptions of SOB severity from the focus group sessions, including ''did not do'' to account for adaptation by the patient. Some patients stated that they had difficulty interpreting what ''I did not do'' meant to them. To clarify the meaning of this response option, ''I did not do'' was changed to ''I did not do the activity today.'' In addition, some activities may or may not be performed because of gender; however, the majority of patients stated that their gender did not impact whether they performed the activities listed on the questionnaire.
Cognitive Debriefing Discussions
Patient demography and clinical characteristics
Phase 2 consisted of cognitive debriefing interviews. A total of 37 patients participated in these interviews over a 3-month period: 10 patients participated in the first round, 10 patients in the second round, 5 patients in the third round, and 12 patients in the fourth round. The patients' demographic and clinical characteristics are provided in Table 1 . Each interview lasted 1.5 to 2 hours. Overall, the SOBDA questionnaire was well received: patients confirmed that the questionnaire was clear and easy to understand and captured most daily activities. Patients reported that the items were, in general, relevant to their experiences with breathing problems while performing their daily activities. However, those with more severe COPD found some of the items to be less relevant because they were not able to do the activities. In addition, patients were asked whether their gender affected their likelihood of undertaking activities on the questionnaire; the majority said ''no.'' The SOBDA questionnaire is intended to be used as a daily diary. However, several interviews were conducted in the morning, which made it difficult for patients to think about their experiences ''today'' because it was early. A few patients stated that they thought of a ''typical day'' or ''yesterday'' when completing the questions. The patients stated that the instructions and response options on the questionnaire made it very clear that the time frame is ''today,'' meaning the period of time from when they woke up until they went to bed and that patients should complete the questionnaire before they go to bed at the end of the day.
Fourth Round of Cognitive Debriefing Interviews
Following consultation with the FDA, feedback was received stating that illustrating an activity with a specific body position might imply a requirement to perform the activity in that position, while in practice there is variation (e.g., some participants may brush their teeth while standing up instead of bending over the sink). Consequently, the stick figure illustrations were removed to avoid the risk of confusion or nonresponse (''did not do the activity today''). The response options and instructions were also modified on the basis of FDA feedback.
The resulting version (Version 1.4) was presented to patients in the fourth round of cognitive debriefing interviews. Participants with less severe COPD found some items to be less relevant to their SOB experiences, but the range of items successfully ensured applicability across a wide range of patients. Patients using Version 1.4 reported that the instructions were clear and easy to understand. Their explanations of what the instructions and time frame meant were appropriate and indicated correct interpretation.
Electronic Format User Acceptability
During all the cognitive debriefing interviews, patients were briefly instructed on how to use the electronic questionnaire, and then asked to answer SOBDA questionnaire items by using a personal digital assistant. During the first three rounds of interviews, participants reported that the electronic format was easy to use and that they would not have a problem using the device in a study. In the fourth round, patients who commented on the use of the personal digital assistant did not report any difficulty.
Discussion
In developing an instrument to assess disease symptoms from the patient perspective, the use of patient-based terminology is critical. The SOBDA questionnaire was developed by using a patientcentered approach to the terminology and structure, and patients considered the resulting questionnaire to be clear and easy to understand. In addition, in order to account for possible issues regarding translatability and cultural differences, four translation experts and one lexibility expert reviewed the conceptual model and provided feedback on its relevance in specific countries and at the global level and on the overall translatability of the instrument. In accordance with standard cross-cultural translation and adaption processes, adjustments were made throughout the development of the SOBDA questionnaire to create an instrument with items that were understandable across cultures, at the appropriate reading grade level for all patients, particularly in areas of limited health literacy, and that could be utilized in clinical trials worldwide [25] .
Patients with COPD usually use the term ''shortness of breath'' to describe their dyspnea [29] [30] [31] [32] [33] [34] [35] [36] . Patients with COPD perceive SOB as one of the major symptoms impairing their quality of life and well-being. Ho et al. [8] reported that patients experiencing dyspnea scored significantly lower in all four domains (mobility, kitchen, domestic and leisure activities) of the Nottingham Extended Activities of Daily Living index than do those not experiencing dyspnea [37] . Mobility tasks were affected to the greatest extent. There was also a significant difference in total Hospital Anxiety and Depression Scale scores between dyspneic subjects and nondyspneic subjects, suggesting that breathing problems are associated with anxiety and depression [37] [38] [39] [40] [41] . Patients have described dyspnea as being ''hard work'' [42] , ''a constant struggle'' [43, 44] , ''a continuous fight'' [45] , ''painful,'' ''taking all one's strength,'' and ''exhausting'' [44] . Study participants often find it difficult to convey their personal experience of dyspnea to others. Nicholls [44] observed that patients may instead describe dyspnea by creating mental pictures: ''a dark cloud,'' ''a battle,'' ''a wall,'' or metaphorically, describing that ''life was closing in'' or that they needed to ''steer a careful course'' if dyspnea was unpredictable. However, such descriptions are difficult to quantify, necessitating the use of other measures to capture patient experiences. Previously developed PRO questionnaires do not adequately address the dyspnea component of COPD or meet FDA standards for instrument development. For example, the St. George's Respiratory Questionnaire for COPD patients and other measures such as Chronic Respiratory Questionnaire -Self-Administered Standardized (although well used) have not undergone rigorous study in terms of content validity and ability to reflect patient voice. The FDA requires content validity and saturation of data to be demonstrated for PROs in order for the data to support labeling and promotional claims [13] .
In line with FDA guidance, this research was designed to gather qualitative evidence to inform the development of a new PRO instrument, with a focus on measuring the effect of dyspnea on the daily activities of patients with COPD. An important component of qualitative research is establishing content validity. Content validity is the extent to which the content of an instrument represents the most important aspects of a given concept [46] . In the FDA guidance on PRO measurement, content validity is defined as evidence that the items and domains of an instrument are appropriate and are comprehensive relative to its intended measurement concept, population, and use [13] . Such evidence includes documentation from qualitative research, which demonstrates that the PRO instrument measures the concept of interest. In addition, qualitative patient data are essential for establishing content validity of a PRO instrument. Content validity is essential for the interpretability of the concept measured. Qualitative data in the current evaluation were collected through focus groups with patients with COPD, reviewed by experts in pulmonary research to assess content validity from a clinical perspective, reviewed by translation experts to minimize potential translation difficulties and cross-cultural differences, and discussed during cognitive debriefing interviews with patients to ensure that the draft instrument remained understandable and relevant. The usability of the SOBDA questionnaire on an electronic device was also assessed. The extensive involvement of patients with characteristics typical of those with COPD ensured that the questionnaire effectively reflects patients' own perspectives.
This article highlights the most important issues and ideas that came out of the focus groups. The terminology used by patients to describe the sensation of dyspnea (SOB), and the varying degrees of SOB associated with everyday activities and hobbies, was the primary focus of discussion. Patients were able to distinguish SOB from chest congestion, wheezing, and chest tightness, and most often described their experience with terms such as ''short of breath'' and ''difficulty breathing.'' Focus group transcripts were central to the development of the item pool. Items were derived from patient comments and experiences related to everyday activities. Stick figure illustrations VA L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 4 2 -1 0 5 0 were initially included within the instrument because of the reported impact of body position on SOB. The illustrations were later removed from the questionnaire following feedback received from the FDA. It is anticipated, however, that they will be useful during the process of translating the questionnaire as they provide additional information to ensure cross-cultural equivalence. The qualitative data obtained during the cognitive debriefing interviews were used to confirm the content validity of items selected for the SOBDA questionnaire. Overall, descriptions of dyspnea did not vary across the GOLD stages. The activities listed in the questionnaire represented everyday experiences for GOLD stage I to GOLD stage IV patients, although GOLD stage I patients reported SOB difficulty only when doing physically demanding activities. The questions were designed to measure dyspnea associated with daily activities across a wide range of disease severity to ensure suitability of the SOBDA questionnaire for all patients with COPD.
Conclusions
Qualitative research with patients with COPD was the basis for developing the SOBDA questionnaire. Patients included in the research had the full range of COPD severity and a wide spread across both socioeconomic status and ethnicity. Concept saturation was reached during patient focus groups. Comments from the FDA were carefully considered, and appropriate revisions were made. The item pool contains 37 items to assess SOB associated with everyday activities. Instructions and response options were well understood by patients with COPD, and the items' relevance was confirmed. Scoring, scaling, reliability, validity, and responsiveness will be assessed in future prospective validation studies.
